Advertisement
MGNX vs VYGR
Which Stock Would AI Choose? MacroGenics (MGNX) vs. Voyager Therapeutics (VYGR) Stock Comparison
Key Takeaways
- MGNX is an oncology-focused biotech advancing antibody-drug conjugates (ADCs) and bispecific antibodies, while VYGR develops gene-based therapies for neurological diseases.
- MacroGenics has executed a business transformation—divesting manufacturing and monetizing royalties—extending its cash runway through 2028.
- Voyager Therapeutics holds high-profile partnerships with Novartis and Neurocrine but remains pre-revenue and heavily reliant on collaboration income.
- Analyst sentiment is stronger on VYGR by rating (Strong Buy consensus), yet MGNX has shown more visible recent price momentum and a broader set of near-term catalysts.
- Both stocks are speculative, clinical-stage names with distinct risk profiles tied to oncology versus central nervous system (CNS) drug development.
Introduction
Investors screening the small- and mid-cap biotechnology space often compare companies at similar stages of development but in different therapeutic domains. This stock comparison examines MGNX, MacroGenics, an oncology-focused developer of antibody-based cancer therapies, and VYGR, Voyager Therapeutics, a specialist in gene therapies for neurological conditions. Both are clinical-stage businesses without broad commercial products, making relative performance, pipeline catalysts, and market positioning key considerations. This comparison is most relevant for investors and traders comfortable with elevated volatility and long development timelines who want a fact-based view of how two distinct biotech models stack up in the current environment.
MGNX Overview and Recent Performance
MacroGenics (MGNX) develops antibody-based cancer therapeutics, including antibody-drug conjugates (ADCs) and multi-specific DART and TRIDENT molecules. Its lead clinical programs include MGC026, a B7-H3-targeting ADC, and MGC028, an ADAM9-targeting ADC, alongside lorigerlimab, a bispecific antibody targeting PD-1 and CTLA-4. In recent quarters the company reported rising revenue, driven by contract manufacturing and royalty income from the partnered product ZYNYZ, while narrowing its net loss year over year.
Recent market activity has been shaped by a broader business transformation. MacroGenics announced the divestiture of its manufacturing operations to Bora for up-front proceeds of roughly $122.5 million and expanded a ZYNYZ royalty monetization arrangement with Sagard, receiving about $60 million. Management has guided that these moves, together with partner payments, support a cash runway through 2028. On the clinical side, the lorigerlimab LINNET study experienced an earlier partial clinical hold tied to safety events, though the company has since outlined a lower-dose strategy for clear cell gynecologic cancer. Analyst upgrades and price-target increases have accompanied these developments, and the shares have shown notable relative strength over recent months.
VYGR Overview and Recent Performance
Voyager Therapeutics (VYGR) applies human genetics to develop gene-based medicines for neurological diseases, anchored by its TRACER adeno-associated virus (AAV) capsid discovery platform. Its pipeline includes VY7523, an anti-tau antibody for Alzheimer's disease, and VY1706, a tau-silencing gene therapy, alongside programs in Friedreich's ataxia, Parkinson's disease, and ALS. The company generates revenue primarily through collaborations with Novartis and Neurocrine.
In recent quarters, Voyager has reported declining collaboration revenue and a shrinking cash balance, though it continues to narrow operating losses through cost-cutting initiatives. Management expects cash, together with collaboration reimbursements, to fund operations into 2028. Sentiment has been mixed: the stock carries a Strong Buy consensus among analysts, with price targets implying significant potential upside, yet the shares have traded near multi-year lows in recent market activity and insider selling has been reported. Key near-term catalysts include clinical data readouts from its anti-tau programs, which carry binary, high-impact risk.
Trending AI Robots
For investors who prefer a systematic approach to navigating volatile sectors like biotechnology, Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only the strongest performers—those best suited to current market conditions—earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, allowing users to match automation to their own objectives. Browsing the Trending AI Robots list can help traders observe how algorithmic strategies are positioning across names like MGNX and VYGR in real time.
Head-to-Head Comparison
The two companies diverge most sharply in therapeutic focus and revenue model. MacroGenics is an oncology play with multiple wholly owned ADC programs and royalty-generating partnerships, giving it a more diversified pipeline and a near-term path to non-dilutive cash via its restructuring. Voyager is concentrated in neurology and gene therapy, where development timelines are long and outcomes uncertain, but where its platform has been validated by marquee collaborations.
On momentum, MacroGenics has displayed more visible recent upward price behavior and a steady stream of corporate catalysts. Voyager, by contrast, trades at depressed levels despite a stronger analyst rating profile, reflecting market skepticism about near-term value creation. Risk profiles also differ: MacroGenics faces clinical-safety overhang from its lorigerlimab program, while Voyager carries execution risk around early-stage CNS data and dependence on partner milestones. Sector exposure—oncology versus CNS—further distinguishes the two for investors seeking either category exposure.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor MGNX in the current environment. The stock demonstrates comparatively stronger trend consistency, a more diversified pipeline, and a clearer set of near-term catalysts, supported by improved liquidity from its restructuring. While VYGR benefits from a stronger consensus rating and notable partner validation, its recent price action and reliance on binary, longer-dated clinical events introduce greater uncertainty. This assessment is probabilistic and reflects current positioning rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGNX is a StrongBuy and VYGR is a StrongBuy.
Momentum Indicator for MGNX turns positive, indicating new upward trend
MGNX saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 78 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on October 21, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MGNX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.393) is normal, around the industry mean (2.973). P/E Ratio (-16.500) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VYGR's RSI Indicator entering oversold zone
The RSI Oscillator for VYGR moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +15.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 229 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for VYGR crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.742) is normal, around the industry mean (2.973). P/E Ratio (-1.028) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MGNX | VYGR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 45 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 47 | 89 | |
P/E GROWTH RATING 1..100 | 23 | 14 | |
SEASONALITY SCORE 1..100 | 90 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VYGR's Valuation (45) in the Biotechnology industry is somewhat better than the same rating for MGNX (86). This means that VYGR’s stock grew somewhat faster than MGNX’s over the last 12 months.
VYGR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MGNX (100). This means that VYGR’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's SMR Rating (97) in the Biotechnology industry is in the same range as VYGR (98). This means that MGNX’s stock grew similarly to VYGR’s over the last 12 months.
MGNX's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for VYGR (89). This means that MGNX’s stock grew somewhat faster than VYGR’s over the last 12 months.
VYGR's P/E Growth Rating (14) in the Biotechnology industry is in the same range as MGNX (23). This means that VYGR’s stock grew similarly to MGNX’s over the last 12 months.
| MGNX | VYGR | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 86% | N/A |
| MACD ODDS (%) | 1 day ago 83% | N/A |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 84% |
| Advances ODDS (%) | 1 day ago 85% | 3 days ago 83% |
| Declines ODDS (%) | 9 days ago 84% | 1 day ago 82% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MGNX’s FA Score shows that 1 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).
- MGNX’s FA Score: 1 green, 4 red.
- VYGR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MGNX’s TA Score shows that 5 TA indicator(s) are bullish while VYGR’s TA Score has 4 bullish TA indicator(s).
- MGNX’s TA Score: 5 bullish, 4 bearish.
- VYGR’s TA Score: 4 bullish, 3 bearish.
Price Growth
MGNX (@Biotechnology) experienced а +7.72% price change this week, while VYGR (@Biotechnology) price change was -9.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
MGNX is expected to report earnings on Nov 11, 2026.
VYGR is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MGNX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with KRRO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then KRRO could also see price increases.
| Ticker / NAME | Correlation To MGNX | 1D Price Change % | ||
|---|---|---|---|---|
| MGNX | 100% | +1.11% | ||
| KRRO - MGNX | 45% Loosely correlated | +29.71% | ||
| VYGR - MGNX | 44% Loosely correlated | -7.92% | ||
| AMRN - MGNX | 44% Loosely correlated | +0.78% | ||
| ZVRA - MGNX | 41% Loosely correlated | -0.29% | ||
| MLTX - MGNX | 34% Loosely correlated | +15.87% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| YLDE | 57.71 | 0.64 | +1.12% |
| Franklin ClearBridge Enhanced Income ETF (YLDE) | |||
| BDCZ | 13.73 | 0.13 | +0.94% |
| ETRACS MarketVector Business Development Companies Liquid Index ETN (BDCZ) | |||
| IBIL | 24.28 | 0.22 | +0.93% |
| iShares iBonds Oct 2035 Term TIPS ETF (IBIL) | |||
| FISR | 24.82 | 0.21 | +0.85% |
| State Street Fixed Income Sector Rotation ETF (FISR) | |||
| COPX | 73.13 | -4.89 | -6.27% |
| Global X Copper Miners ETF (COPX) | |||